COVID-END funding update

COVID-END Partners’ Meeting
4 Nov 2021

John N. Lavis, MD PhD, Co-PI, COVID-END in Canada; Director, McMaster Health Forum; and Professor, McMaster University

Jeremy Grimshaw, MBChB PhD, Co-PI, COVID-END in Canada; Senior Scientist, Ottawa Hospital Research Institute; and Professor, University of Ottawa

Andrea Tricco, PhD, Co-PI, COVID-END in Canada; PI, SPOR Evidence Alliance; Scientist, Unity Health Toronto; and Assoc Professor, University of Toronto

Nancy Santesso, PhD, Co-PI, COVID-END in Canada; Deputy Director, Cochrane Canada; Assist Professor, McMaster University
COVID-END

- COVID-END was formed in April 2020 as a time-limited network of international evidence synthesis, recommendation and intermediary organisations that came together in response to the ‘exogenous shock’ of the pandemic COVID-19 to promote collaboration and co-operation among the evidence community (and reduce inappropriate duplication of effort)
COVID-END funding (Phase 1)

- March 2020-December 2020 funded by:
  - Government of Ontario, CAN (re-purposed funding)
  - National Institutes of Health Research, UK
  - Philanthropists through the Centre for Effective Altruism and Fidelity Charitable and individual donors, USA
- Supported COVID-END global activities
COVID-END funding (Phase 2)

- December 2020 – November 2021 funded by Canadian Institutes for Health Research (COVID-END, SPOR Evidence Alliance, Cochrane Canada)
- Funding supported:
  - Canadian activities
    - Rapid syntheses requested by Canadian decision-makers
    - Evidence demand and supply coordination
    - Horizon scanning
  - Global activities
    - Inventory
    - Horizon scanning
    - Global partnership
COVID-END funding (Phase 2)

Achievements

- 86 new or updated evidence syntheses
- 12 living evidence syntheses
- Pool of 20 Canadians to provide citizen perspectives on syntheses
- Canadian evidence demand and supply coordination
- Bimonthly global and Canadian newsletters
- Monthly Canadian and global horizon scanning
- Maintained inventory (reduced noise to signal from 10,740 syntheses to 584 ‘best’ evidence syntheses)
- Many more activities supported through the funding (partners’ meetings, working groups, citizen engagement, COVID-END community and listserv, WHO ECC-19 secretariat)
- Global Commission on Evidence to Address Societal Challenges
COVID-END funding (Phase 3)

- December 2021 – November 2022 (application pending) funding by Canadian Institutes for Health Research (COVID-END, SPOR Evidence Alliance, Cochrane Canada); largely a continuation of previous funding

- Key changes:
  - Maureen Smith added as a Co-PI
  - Less resource intensive horizon scanning
  - Some support for the Global Commission pathways to influence
  - Review of global partner activities
Beyond COVID-END (Dec 2022)

- John Lavis, Kaelen Moat, Ileana Ciurea, Safa Al-Khateeb, FP Gauvin, Jenn Verma, Michael Wilson, Jeremy Grimshaw, Andrea Tricco, Nancy Santesso, Maureen Smith all spotted on DIFFERENT beaches
Summary

- Good (?) news, ongoing funding for COVID-END Canadian and global activities
- Need to review activities and ensure sustainability of activities for the team.